iBio

iBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics. It operates through the Biopharmaceuticals and Bioprocessing segments. The Biopharmaceuticals segment involves molecule discovery, development, and licensing activities. The Bioprocessing segment includes contract development and manufacturing services for recombinant proteins. The company was founded on April 17, 2008 and is headquartered in Bryan, TX.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q1 2025

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. It focuses on decreasing drug failures, shortening drug development timelines and opening up new frontiers against the most promising targets. The company was founded on April 17, 2008 and is headquartered in San Diego, CA.

Yes, I will continue to root for Ibio in its fight to make a huge leap with its Covid-19 efforts. But where my investment dollar is concerned, it'll be from the sidelines.

IBIO Stock Remains a Speculative Biopharma Play

The time to make money by investing in iBio is over. Here's why that's good news.

Is It Too Late to Buy iBio Stock?

With the viable candidate pool for novel coronavirus vaccines shrinking, this angle is probably closed to IBIO stock. However, speculators still have a shot with the therapeutic approach.

The Low-Hanging Fruit for Covid-19 Vaccines Is Gone for iBio

- Adds More Than 25 Years of Financial Leadership in Pharma / Biotech to the Team - 

Accomplished Financial Executive, Gary Sender, Joins iBio’s Board of Directors

- Senior Biopharm Executive with 20 Years of Immuno-Inflammatory Disease Therapeutic Experience -

iBio Announces Appointment of Dr. Alexandra Kropotova to Board of Directors

- Accomplished Biopharm Exec with Years of Clinical Experience in Respiratory Diseases -

iBio Announces Appointment of Dr. Linda Armstrong to Board of Directors

IBIO stock is a purely speculative bet compared to better options when it comes to investing in Covid-19 vaccine development. The post IBIO Remains a Purely Speculative Bet appeared first on InvestorPlace.

IBIO Remains a Purely Speculative Bet

An investment in IBIO stock is a bet on the company’s unique FastPharming system to create medications and therapies of all sorts. The post Why iBio Is a Buy for Investors Thinking Past the Vaccine Race appeared first on InvestorPlace.

Why iBio Is a Buy for Investors Thinking Past the Vaccine Race

IBIO stock is in a rough spot with minimal progress in its Covid-19 vaccine and its FastPharming technology. The post IBio Stock Is Not Worth a Gamble at This Stage appeared first on InvestorPlace.

IBio Stock Is Not Worth a Gamble at This Stage

BRYAN, Texas, Oct. 13, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced its financial results for the fiscal year ended June 30, 2020, which included record revenues of over $1.1 million in the fiscal fourth quarter.

iBio Announces Financial Results for Fiscal Year Ended June 30, 2020

Since hitting $1.70 on Aug. 21, IBIO stock has gone sideways. With little on the news front over the past seven weeks, it’s easy to see why.

A Dice-Roll on iBio Stock Is Much Less Appealing Now

Most bulls buying into IBIO stock the past few months are underwater. But that short-term pain may have finished.

At This Stage of the Vaccine Race, Is Now a Good Time to Buy iBio Stock?

With no real vaccine news to speak of, I’d avoid the IBIO stock for now. If they can get something going, it may be worth a look.

This Is Why I’d Still Avoid IBio for Now

NEW YORK, Oct. 05, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, announced today that on October 1, 2020, the Company received written notice from the NYSE American LLC (“NYSEA” or the “Exchange”) stating that the Company had regained compliance with all of the Exchange’s continued listing standards set forth in Part 10 of the NYSEA Company Guide (“Company Guide”).

iBio Regains Compliance with NYSE American Continued Listing Standards

Investors pondering how a company with a history of moving back-and-forth between micro- and small-cap territory could adequately compete against more well-heeled rivals were right to express those concerns and IBIO stock validated those worries. The post iBio Will Survive Coronavirus Vaccine Disappointment, But It’s not a ‘Buy’ appeared first on InvestorPlace.

iBio Will Survive Coronavirus Vaccine Disappointment, But It’s not a ‘Buy’

IBIO stock will continue to ebb and flow as the pandemic rages on. Day traders should look out for positive clinical trial news as a buy-in signal.

iBio Is a Pure Spec Play That Remains a Day Trader’s Delight

After some serious run-ups and drops through 2020, IBIO stock lacks the financial muscle to make it worthy of long-term investment. The post If You’re Not a Speculator, You Should Avoid iBio appeared first on InvestorPlace.

If You’re Not a Speculator, You Should Avoid iBio

- Project Focused on Proteins used in the Production of Blood Cells -

iBio Enters into Agreement with Safi Biosolutions to Develop Growth Factors and Cytokines Using the FastPharming® System

DocuSign

Netflix

Slack

Zoom Video

These stay-at-home stocks are trading at premium valuations but should start cooling down as the effects of the virus wear off. The post 5 Stay-At-Home Stocks That Won’t Be the New Normal appeared first on InvestorPlace.

5 Stay-At-Home Stocks That Won’t Be the New Normal

A unique plant-based approach makes IBIO stock a quality name for investors looking for a plan on a novel coronavirus vaccine.
The post Unique Vaccine Solutions Make iBio Stock a Buy Now appeared first on InvestorPlace.

Unique Vaccine Solutions Make iBio Stock a Buy Now

As I detailed earlier this month, there are many pandemic vaccine plays out there with greater chances of success. That's not to say these rival candidates will find success.

Scant Vaccine Hopes Aren’t Enough to Make iBio a Buy

IBIO stock has faded from its highs with good reason: the company isn't giving investors enough reason to jump in.
The post There Simply Isn’t Enough Good News for iBio appeared first on InvestorPlace.

There Simply Isn’t Enough Good News for iBio

IBIO stock still represents hope for a vaccine. But perhaps it may be time to judge it as a pack member rather than an alpha dog.

IBio is Still Sitting in the Starting Gates of the Vaccine Race

A recent deal on developing a Covid-19 therapy is getting attention but IBIO stock is still a very speculative play in the biopharma space.

Vaccine Wanna-be iBio Stock Remains a Gamble Even After New Partnership

IBIO stock isn't the coronavirus vaccine bet investors should pursue, with its candidates in pre-clinical stages showing minimal promise.
The post iBio Is a Wishful Thinkers Coronavirus Vaccine Bet appeared first on InvestorPlace.

News for iBio Stock (IBIO)